IQVIA Holdings Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From IQVIA Holdings Inc.
Looking Beyond The Deal In England
Agreement of deals that promise better value for money and enhanced patient access to new treatments has become routine in England, but are they delivering?
Scrip Asks…What Does 2023 Hold For Biopharma? Part 6: Artificial Intelligence
The biopharma industry may not have been the fastest adopter of artificial intelligence, but its vast potential means companies of every shape and size know they cannot ignore it. Executives, advisors and investors share their predictions around the impact of AI in 2023.
Collaboration Makes The (Real) World Go Round: Global Efforts Strive To Anchor RWE With Real-World Data Standards And Practices
Can the decentralized global healthcare ecosystem to turn real-world evidence from a buzzword to a useful approach to fit-for-purpose evidence generation?
Acticor Makes Case For First-In-Class Heart Drug Glencozimab
As it initiates the mid-stage clinical program for glencozimab, Acticor says that the potential of the drug in ischemic stroke alone could make it a blockbuster.
- Contract Research Organization-CRO
- Other Names / Subsidiaries
- IMS Health, IQVIA Biotech LLC, Novasyte, LLC
- Myriad RBM Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.